Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Mankind Pharma will invest ₹479.60 Crore into its Dutch subsidiary to acquire a majority 70% stake in Belgian biotech firm ACTx, strengthening its innovation-led portfolio.